Analysis

Two of a kinD (Kidneys in Diabetes)

The burden of diabetic kidney disease

This report for Kidney Health Australia examines the burden of diabetic kidney disease and the cost effectiveness of screening people with type 2 diabetes for chronic kidney disease.

Type 2 diabetes is now the leading cause of life threatening kidney disease in Australia, with the two conditions forming an interrelated and sinister relationship called ‘diabetic kidney disease’.

In 2010, there were approximately 1.7 million people in Australia with chronic kidney disease (CKD). Of these, 282,146 Australians had diabetic kidney disease, a condition that is likely to escalate as both the population ages and the prevalence of diabetes increases.

In patients with type 2 diabetes, kidney disease increases the complications of diabetes including nerve and eye damage, and cardiovascular disease, while poor glycaemic control can accelerate the progression of kidney disease.

Deloitte Access Economics was commissioned by Kidney Health Australia to estimate the economic cost of CKD in people with type 2 diabetes, and to evaluate the cost effectiveness of an Australia wide CKD screening program for all people with type 2 diabetes.

Total economic cost of CKD in people with type 2 diabetes was estimated to be $674.8 million in 2009-10.These costs were projected to increase to $682.7 million by 2015-16, and $914.3 million by 2020-21.

Two of a KinD (Kidneys in Diabetes)
Did you find this useful?